Long Island TS Clinical Trials

Please note the following information regarding important clinical trials being conducted at North Shore Hospital in Manhasset under Cathy Budman, MD, that we would like to bring to the attention of the Long Island TS Community.

Genetics of Tourette Syndrome:

This is a study co-funded by the National Institute of Health/NINDS and the National Tourette Syndrome Association, performed by members of the International Tourette Syndrome Consortium for Genetics. North Shore University Hospital in Manhasset of the North Shore/Long Island Jewish Health System serves as the regional participating site for this study that is being conducted world-wide. We are seeking all persons, both adults and/or children with Tourette Syndrome (TS) to participate in this genetic study which is trying to identify important genes and genetic mechanisms in TS and its related disorders. Participation entails completing a questionnaire about clinical symptoms, demographic information, and history, and providing a single blood sample that will be sent for analysis. Interested individuals can contact Joanna Witkin at 516-562-3224 or by email at jwitkin@nshs.edu, or can call Dr. Cathy Budman at: 516-562-3223.

Does your child struggle with frequent tics caused by Tourette’s Disorder? Learn more about this medical research study evaluating an investigational drug for tics associated with Tourette’s disorder in children or adolescents.

For children with severe, disruptive tics, medication may help, although current treatments often include side effects. North Shore University Hospital in Manhasset is one of twelve sites across the country assessing a new formulation of a drug called aripiprazole (commonly known as Abilify). Potential subjects for this study include children and adolescents ages 7–17 years old diagnosed with Tourette Syndrome and experiencing frequent tics almost daily for over a year, without any tic-free periods of more than three months.

Participation would entail one to three phases of a once weekly dose of aripiprazole. The study duration could range from approximately 90–150 days, including up to 60 days for screening and a followup 30 days after study completion. The subject would come in for at least one overnight visit and several day visits. Qualified participants would receive study drug and study-related medical evaluations at no cost. Reimbursement for time and travel may also be provided.

CONTACT: Dr. Cathy Budman at 516-562-3223 or CBudman@nshs.edu; Study Coordinator Christina Lipinski at (516) 562- 3224 or CLipinski@nshs.edu.

Click to visit the Tourette Association of America Site

Donate to LI Tourette Association

100 % of donated funds go directly to programming for and support of

LI Tourette Association

End of Page